Qiagen : Q3 review – Strong third quarter with guidance increase again
>Q3 a strong beat of expectations - Qiagen’s Q3 revenues of $ 500.0m (-6.5% y-o-y) came in perfectly in line with our forecast and 4% ahead of the consensus. Revenues development at CER was flat, while forex translated to a headwind of 650bp. Adjusted EBIT of $ 144m (-12.5% y-o-y, margin 28.8%) was 2% ahead of ODDO BHF’s estimate, but 12% ahead of the consensus. Adjusted EPS of $ 0.53 was also a beat of 11% of ODDO BHF’s $ 0.48 and by 18% of the consensus’ $ 0.45. §rc...Qiagen is provider of Sample to Insight solutions to transform biological materials into valuable molecular insights. Co.'s sample technologies process DNA, RNA and proteins from blood, tissue and other materials. Assay technologies make these biomolecules visible and ready for analysis. Bioinformatics software interprets data. Automation solutions unite these together in molecular testing workflows. Co. provides these workflows to four classes: Molecular Diagnostics (human healthcare), Applied Testing (forensics, veterinary testing and food safety), Pharma (pharmaceutical and biotechnology companies) and Academia (life sciences research). Co. markets its products in more than 130 countries.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.